Cyclophosphamide, vindesine and oral VP-16 in the treatment of non-small cell lung cancer (NSCLC): an outpatient regimen.
Twenty-five evaluable patients with non-small cell carcinoma of the lung were treated with cyclophosphamide, vindesine and oral VP-16 in the outpatient setting. The overall response rate was 44% and the median survival was 4.9 months (7.25 months in responders).